Ublituximab
Ublituximab
Ublituximab (pronounced: yoo-bli-TUX-i-mab) is a monoclonal antibody designed for the treatment of certain types of cancer and autoimmune diseases. It is currently under investigation for its potential use in treating Multiple Sclerosis and Chronic Lymphocytic Leukemia.
Etymology
The name 'Ublituximab' follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix '-mab' indicates that it is a monoclonal antibody, while the infix '-tuxi-' suggests its action on the immune system.
Mechanism of Action
Ublituximab works by binding to a specific protein called CD20, which is found on the surface of B cells, a type of white blood cell. By binding to CD20, Ublituximab triggers the immune system to destroy these cells, thereby reducing the number of harmful B cells in the body.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- B cells: A type of white blood cell that makes antibodies.
- CD20: A protein found on the surface of B cells.
- Multiple Sclerosis: A disease in which the immune system eats away at the protective covering of nerves.
- Chronic Lymphocytic Leukemia: A type of cancer of the blood and bone marrow where too many blood cells are produced.
External links
- Medical encyclopedia article on Ublituximab
- Wikipedia's article - Ublituximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski